Literature DB >> 26177934

Triazole linker-based trivalent sialic acid inhibitors of adenovirus type 37 infection of human corneal epithelial cells.

Rémi Caraballo1, Michael Saleeb, Johannes Bauer, A Manuel Liaci, Naresh Chandra, Rickard J Storm, Lars Frängsmyr, Weixing Qian, Thilo Stehle, Niklas Arnberg, Mikael Elofsson.   

Abstract

Adenovirus type 37 (Ad37) is one of the principal agents responsible for epidemic keratoconjunctivitis (EKC), a severe ocular infection that remains without any available treatment. Recently, a trivalent sialic acid derivative (ME0322, Angew. Chem. Int. Ed., 2011, 50, 6519) was shown to function as a highly potent inhibitor of Ad37, efficiently preventing the attachment of the virion to the host cells and subsequent infection. Here, new trivalent sialic acid derivatives were designed, synthesized and their inhibitory properties against Ad37 infection of the human corneal epithelial cells were investigated. In comparison to ME0322, the best compound (17a) was found to be over three orders of magnitude more potent in a cell-attachment assay (IC50 = 1.4 nM) and about 140 times more potent in a cell-infection assay (IC50 = 2.9 nM). X-ray crystallographic analysis demonstrated a trivalent binding mode of all compounds to the Ad37 fiber knob. For the most potent compound ophthalmic toxicity in rabbits was investigated and it was concluded that repeated eye administration did not cause any adverse effects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26177934     DOI: 10.1039/c5ob01025j

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  14 in total

Review 1.  Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D.

Authors:  Ashrafali Mohamed Ismail; Xiaohong Zhou; David W Dyer; Donald Seto; Jaya Rajaiya; James Chodosh
Journal:  FEBS Lett       Date:  2019-12-11       Impact factor: 4.124

Review 2.  Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies.

Authors:  Mackenzie J Dodge; Katelyn M MacNeil; Tanner M Tessier; Jason B Weinberg; Joe S Mymryk
Journal:  Antiviral Res       Date:  2021-02-10       Impact factor: 5.970

3.  Synthesis of a New Series of Sialylated Homo- and Heterovalent Glycoclusters by using Orthogonal Ligations.

Authors:  Gour Chand Daskhan; Carlo Pifferi; Olivier Renaudet
Journal:  ChemistryOpen       Date:  2016-07-22       Impact factor: 2.911

4.  Sialic Acid-Containing Glycans as Cellular Receptors for Ocular Human Adenoviruses: Implications for Tropism and Treatment.

Authors:  Naresh Chandra; Lars Frängsmyr; Sophie Imhof; Rémi Caraballo; Mikael Elofsson; Niklas Arnberg
Journal:  Viruses       Date:  2019-04-27       Impact factor: 5.048

5.  Decoy Receptor Interactions as Novel Drug Targets against EKC-Causing Human Adenovirus.

Authors:  Naresh Chandra; Lars Frängsmyr; Niklas Arnberg
Journal:  Viruses       Date:  2019-03-12       Impact factor: 5.048

Review 6.  The Symmetry of Viral Sialic Acid Binding Sites-Implications for Antiviral Strategies.

Authors:  Nils H Rustmeier; Michael Strebl; Thilo Stehle
Journal:  Viruses       Date:  2019-10-14       Impact factor: 5.048

Review 7.  Adenovirus Structure: What Is New?

Authors:  José Gallardo; Marta Pérez-Illana; Natalia Martín-González; Carmen San Martín
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

8.  Synthesis of 4-O-Alkylated N-Acetylneuraminic Acid Derivatives.

Authors:  Emil Johansson; Rémi Caraballo; Mikael Elofsson
Journal:  J Org Chem       Date:  2021-06-17       Impact factor: 4.354

Review 9.  Glycomics and Proteomics Approaches to Investigate Early Adenovirus-Host Cell Interactions.

Authors:  Lisa Lasswitz; Naresh Chandra; Niklas Arnberg; Gisa Gerold
Journal:  J Mol Biol       Date:  2018-05-07       Impact factor: 5.469

10.  Entry of Epidemic Keratoconjunctivitis-Associated Human Adenovirus Type 37 in Human Corneal Epithelial Cells.

Authors:  Ji Sun Lee; Santanu Mukherjee; Jeong Yoon Lee; Amrita Saha; James Chodosh; David F Painter; Jaya Rajaiya
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-08-03       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.